The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...

Here's when you can get the FDA-approved, daily pill version of Novo Nordisk's wildly popular GLP-1 drug Wegovy.

The race to treat obesity with powerful new medicines has become one of the defining stories in global healthcare, and Novo ...

As Novo Nordisk’s weight-loss pill Wegovy (semaglutide) readies for a launch in the United States early January, it will be a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Pharmaceutical giants like Lilly and Nordisk are battling for dominance in India’s weight-loss market with price cuts and ...

Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.

Hyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming ...

Novo Nordisk (NVO) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human ...

AstraZeneca's MFN pricing agreement with the US government reflects broader efforts to reduce drug prices and enhance ...